GlassScriptPhysician profile
Kenneth J Bescak
NPI 1164401592
$46,270.34
in general payments reported to CMS, 2019-2025
31 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $465 · 2021: $3,672 · 2022: $9,193 · 2023: $914 · 2024: $1,090 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23,531.29 | 2019-2024 | Repatha, Evenity, Prolia |
| Regeneron Healthcare Solutions, INC. | $11,637.53 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $7,229.39 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,107.59 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $611.85 | 2019-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $460.08 | 2019-2023 | Livalo |
| Edwards Lifesciences Corporation | $312.87 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $205.53 | 2019-2021 | |
| Boston Scientific Corporation | $189.80 | 2021-2025 | Latitude Communicator Power Supply, Cds - Mct/Cem Monitoring |
| Esperion Therapeutics, INC. | $104.95 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $100.77 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $89.10 | 2019-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $88.39 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $72.45 | 2024 | Arcalyst |
| Abbott Laboratories | $67.82 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $58.19 | 2023-2024 | |
| Philips North America LLC | $53.89 | 2023 | |
| Chiesi USA, INC. | $42.24 | 2025 | Juxtapid |
| Merck Sharp & Dohme LLC | $40.76 | 2021 | |
| Pfizer INC. | $36.21 | 2019-2022 | |
| Amryt Pharma Holdings LTD | $35.81 | 2021-2022 | |
| Novo Nordisk INC | $34.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.96 | 2019 | |
| Medicure Pharma INC. | $22.82 | 2025 | Zypitamag |
| Grifols USA, LLC | $22.50 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $21.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.05 | 2024 | |
| Aegerion Pharmaceuticals, INC. | $15.12 | 2019 | |
| Allergan, INC. | $11.45 | 2019 | |
| Corcept Therapeutics | $10.86 | 2019 | |
| Travere Therapeutics, INC. | $3.19 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Bescak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.